Physician profile
Meena K Singh
NPI 1275700528
$180,948.22
in general payments reported to CMS, 2019-2025
47 companies · $79K in 2025
The $79K reported for 2025 was more than what 97% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,823 · 2020: $865 · 2021: $1,079 · 2022: $3,425 · 2023: $58K · 2024: $37K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $110K · Consulting Fee: $27K · Travel and Lodging: $21K · Food and Beverage: $10K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,415 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $110,218.75 |
| Consulting Fee | $27,353.75 |
| Travel and Lodging | $20,507.20 |
| Food and Beverage | $10,112.16 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,415.00 |
| Education | $149.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $83,157.65 | 2019-2025 | |
| Lilly USA, LLC | $47,421.81 | 2019-2025 | Olumiant, Taltz, Zepbound |
| Sun Pharmaceutical Industries INC. | $21,133.35 | 2019-2025 | Ilumya, Winlevi |
| Abbvie INC. | $16,768.53 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Arcutis Biotherapeutics, INC. | $5,100.31 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $705.80 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $649.06 | 2019-2025 | |
| Amgen INC. | $585.59 | 2020-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $536.85 | 2022-2025 | Sotyktu |
| Ucb, INC. | $513.88 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $457.89 | 2019-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $428.11 | 2019-2024 | |
| Kerecis Limited | $349.29 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Genzyme Corporation | $335.88 | 2019-2024 | |
| Revance Therapeutics, INC. | $331.36 | 2024-2025 | Daxxify |
Show all 46 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meena Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.